342 related articles for article (PubMed ID: 17044079)
1. Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics.
Gosselaar C; Roobol MJ; Roemeling S; van der Kwast TH; Schröder FH
Prostate; 2007 Feb; 67(2):154-61. PubMed ID: 17044079
[TBL] [Abstract][Full Text] [Related]
2. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.
Gosselaar C; Roobol MJ; Roemeling S; Schröder FH
Eur Urol; 2008 Sep; 54(3):581-8. PubMed ID: 18423977
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of prostate cancer detected by digital rectal examination only.
Okotie OT; Roehl KA; Han M; Loeb S; Gashti SN; Catalona WJ
Urology; 2007 Dec; 70(6):1117-20. PubMed ID: 18158030
[TBL] [Abstract][Full Text] [Related]
4. Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml).
Vis AN; Hoedemaeker RF; Roobol M; van der Kwast TH; Schröder FH
Prostate; 2001 Jun; 47(4):252-61. PubMed ID: 11398172
[TBL] [Abstract][Full Text] [Related]
5. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
Roobol MJ; Kranse R; de Koning HJ; Schröder FH
Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/mL.
Bozeman CB; Carver BS; Caldito G; Venable DD; Eastham JA
Urology; 2005 Oct; 66(4):803-7. PubMed ID: 16230142
[TBL] [Abstract][Full Text] [Related]
9. Digital rectal examination is barrier to population-based prostate cancer screening.
Nagler HM; Gerber EW; Homel P; Wagner JR; Norton J; Lebovitch S; Phillips JL
Urology; 2005 Jun; 65(6):1137-40. PubMed ID: 15922431
[TBL] [Abstract][Full Text] [Related]
10. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
[TBL] [Abstract][Full Text] [Related]
11. Significance of serum free prostate specific antigen in the screening of prostate cancer.
Higashihara E; Nutahara K; Kojima M; Okegawa T; Miura I; Miyata A; Kato M; Sugisaki H; Tomaru T
J Urol; 1996 Dec; 156(6):1964-8. PubMed ID: 8911366
[TBL] [Abstract][Full Text] [Related]
12. Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease.
Freedland SJ; Mangold LA; Epstein JI; Partin AW
Urology; 2004 May; 63(5):887-91. PubMed ID: 15134972
[TBL] [Abstract][Full Text] [Related]
13. Digital rectal examination as a prostate cancer-screening method in a country with a low incidence of prostate cancer.
Shim HB; Lee SE; Park HK; Ku JH
Prostate Cancer Prostatic Dis; 2007; 10(3):250-5. PubMed ID: 17297501
[TBL] [Abstract][Full Text] [Related]
14. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).
Roobol MJ; van der Cruijsen IW; Schröder FH
Urology; 2004 May; 63(5):892-7; discussion 897-9. PubMed ID: 15134973
[TBL] [Abstract][Full Text] [Related]
15. Role of transperineal six-core prostate biopsy in patients with prostate-specific antigen level greater than 10 ng/mL and abnormal digital rectal examination findings.
Luciani LG; De Giorgi G; Valotto C; Zanin M; Bierti S; Zattoni F
Urology; 2006 Mar; 67(3):555-8. PubMed ID: 16527579
[TBL] [Abstract][Full Text] [Related]
16. [Screening of cancer of the prostate: study in a Spanish population].
Herrero Payo JA; Montes Díaz MJ; Páez Borda A; Sánchez Sánchez E; Moreno Valle JA; Berenguer Sánchez A
Arch Esp Urol; 1996; 49(6):595-606. PubMed ID: 8929102
[TBL] [Abstract][Full Text] [Related]
17. Serial biopsy results in prostate cancer screening study.
Roehl KA; Antenor JA; Catalona WJ
J Urol; 2002 Jun; 167(6):2435-9. PubMed ID: 11992052
[TBL] [Abstract][Full Text] [Related]
18. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
Schröder FH; Bangma CH; Roobol MJ
Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and clinical significance of prostate cancer among 12,682 men with normal digital rectal examination, low PSA levels (< or =4 ng/ml) and percent free PSA cutoff values of 15 and 20%.
Pepe P; Panella P; Savoca F; Cacciola A; D'Arrigo L; Dibenedetto G; Pennisi M; Aragona F
Urol Int; 2007; 78(4):308-12. PubMed ID: 17495487
[TBL] [Abstract][Full Text] [Related]
20. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran.
Hosseini SY; Moharramzadeh M; Ghadian AR; Hooshyar H; Lashay AR; Safarinejad MR
Int J Urol; 2007 May; 14(5):406-11. PubMed ID: 17511722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]